http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100921920-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate | 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-100921920-B1 |
titleOfInvention | Gene therapy for lung cancer |
abstract | The present invention relates to a gene therapy agent for lung cancer that can inhibit cancer metastasis while attacking a cancer tumor. Specifically, a carboxyl terminal modulator protein (CTMP) is used as an agent, and a lentivirus using a lentivirus as a gene carrier. As a result of evaluating the efficiency of vector mediated CTCT and the potential effect of Akt1 on Akt-related signaling and cell cycle regulation, lentiviral-CTMP was delivered to K- ras- depleted lung cancer mice by a nasal suction system. The virus not only significantly inhibited lung tumor development, but also confirmed that aerosol delivery of lentiviral vector mediated-CTMP can be used in combination with invasive in vivo gene therapy.n n n n Lung cancer, CTMP, Akt, lentivirus, aerosol |
priorityDate | 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 347.